Evaluation of inhaled technosphere insulin plus insulin degludec for adults with type 1 diabetes
image: The only peer-reviewed journal covering all aspects of diagnosing and managing diabetes with cutting-edge devices, drugs, drug delivery systems, and software.
Credit: Mary Ann Liebert, Inc.
A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) concluded that inhaled technosphere insulin (TI-Afrezza) should be considered as an option for individuals with type 1 diabetes who want an alternative to using an insulin pump or multiple daily injections (MDI) for insulin delivery. Click here to read the article now.
TI has a more rapid onset of action than rapid-acting insulin analogues. In this study, adults with type 1 diabetes initiated a regimen of TI plus insulin degludec after completing the usual-care control group of a randomized trial.
Roy Beck, MD, PhD, from the JAEB Center for Health Research, and coauthors, reported that daytime time-in-range (TIR) increased from 50+17% to 55+20% with the switch to TI, with an increase of 8.6% compared with baseline MDI and no change compared with baseline automated insulin delivery (AID). Mean HbA1c change from baseline was -0.23%, with mean change -0.36% compared with MDI and 0.0% compared with AID. Participants meeting the HbA1c target of <7.0% increased from 14% to 31%.
“Currently available injectable prandial insulins (lispro, aspart, Lumjev or faster aspart [iASP]do not provide a rapid onset of action. The only insulin that has a rapid on and off effect is TI-Afrezza insulin. The current study by Beck et al. supports improvement in glycemic control, however the total amount of insulin to be taken was significantly higher,” says Satish Garg, MD, Editor-in-Chief of Diabetes Technology & Therapeutics, from University of Colorado Denver, Barbara Davis Center for Diabetes.
About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, University of Colorado Denver, Barbara Davis Center for Diabetes, the Journal covers breakthrough technologies and new therapeutic drug classes, behavioral aspects and approaches to diabetes care, and the latest advancements and applications of new and emerging technologies including continuous glucose monitoring, alternate insulin delivery methods, artificial pancreas, telemedicine and computerized case management, new insulins with ultra-rapid onset of action, and detection and prevention of hypoglycemia. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).
About Mary Ann Liebert, Inc., a Sage Company
Mary Ann Liebert, Inc. is a global media company dedicated to publishing and delivering impactful peer-reviewed research in biotechnology & life sciences, specialized clinical medicine, public health and policy, and technology & engineering. Since its founding in 1980, the company has focused on providing critical insights and content that empower researchers and clinicians worldwide to drive innovation and discovery.